Method of preparing a pharmaceutical composition for regulating lipid concentration comprising using an acyl-CoA cholesterol O-acyltransferase inhibitor and an HMG-CoA reductase inhibitor

摘要

The application is for a combination of an ACAT inhibitor, (for example, sulfamic acid, [[2,4,6,-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester), and an HMG-CoA-reductase inhibitor, (for example, atorvastatin), effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.